Find the latest prostate cancer clinical trials and expert recommendations on diagnostic technology for bladder cancer.
University of Minnesota Cancer Care has announced a clinical trial to test the proposition that MRIs of a higher 7-Tesla field strength will provide increased sensitivity to prostate cancer metabolic markers that are not detectable at lower-field strengths. MRIguided biopsies of the prostate, with or without ultrasound fusion, are usually performed within a 1.5 to 3 Tesla field. In conjunction with other active studies, investigators will assess various field strengths and MRI coil configurations. Adult patients who are under medical care for the prostate gland are eligible to enroll. The primary investigator is Gregory Metzger, PhD, of the University of Minnesota Center for Magnetic Resonance Research. Contact person for the clinical trial is Therese Perrier: 612-625-3319.
University of Minnesota Cancer Care is now enrolling adult patients with localized prostate cancer into a randomized, phase II trial evaluating the effect of a daily pomegranate-extract pill in preventing tumor growth. Animal studies and small studies in humans have suggested that pomegranate extract may slow prostate cancer growth in patients with localized, nonaggressive disease. Eligible patients must be currently managed with active surveillance. Once enrolled, patients take the pomegranate extract daily for 1 year and will undergo 1 follow-up biopsy and a variety of serum biomarker tests over the course of the study. The primary investigator of the study is Badrinath R. Konety, MD, Chair of the Department of Urology at University of Minnesota. Clinical trial contact is Therese Perrier: 612-625-3319.
A focus group of expert urologists, including Badrinath R. Konety, MD, has published recommendations based on a review of clinical evidence and experience on the use of the blue-light cystoscopy technology Cysview. The focus group report that when compared with the use of white-light cystoscopy alone, the use of Cysview for bladder cancer improves detection rates by 20-25%. Current data also support its role in reducing the recurrence of non-muscle-invasive bladder cancer by allowing for more complete resection of tumors. The recommendations appear in Nature Reviews Urology.
This fall, participation in the Prostrate Cancer Research International Active Surveillance (PRIAS) Registry will be available to selected Cancer Care patients. In the registry program, men with indolent prostate cancer are managed with active surveillance, and the outcomes are tracked over time in order to help researchers optimize active surveillance methodologies. Patients on active surveillance are closely monitored using serum PSA levels and other biomarkers and with repeat prostate biopsies. The pursuit of curative treatment or continued observation for individual patients in the registry will be based on evidence of disease progression during the monitoring period. Up to 80% of men with PSA screen-detected prostate cancer have indolent disease and can be managed appropriately with active surveillance. Active surveillance aims to individualize the management of early prostate cancer such that only those men with aggressive disease are recommended for curative treatment, given that treatment can have a large impact upon lifestyle factors and quality of life.
Discover how new technology is improving the detection of bladder and prostate tumors and allowing for their more complete resection.Continue reading
Biopsies on a patient with a history of obstructive urinary symptoms and rising PSA levels produced only negative results. Using a new MRI-ultrasound technology, surgeons were able to locate lesions and successfully treat for prostate cancer.Continue reading